Clinical trial · Observational
China Metastatic Liver Cancer Clinical Registry Cohort Database
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is led by the Department of Hepatobiliary Surgery of the First Affiliated Hospital of the University of Science and Technology of China (USTC), in close collaboration with multiple participating centers nationwide. The primary objective is to establish a standardized, large-scale clinical cohort database specifically for metastatic liver cancer. By collecting comprehensive data on patient demographics, primary tumor characteristics, systemic therapies, and local interventions, this registry aims to elucidate the clinical patterns and prognostic factors of secondary liver malignancies. This database will serve as a robust platform for conducting high-quality real-world studies and advancing evidence-based clinical research in the management of metastatic liver cancer.
Conditions
Conditions (6)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer Metastatic | — | UNRESOLVED | — |
| Liver Cancer | Malignant Liver Neoplasm | CURATED_EXACT | 0.92 |
| Liver Diseases | — | UNRESOLVED | — |
| Liver Metastases | — | UNRESOLVED | — |
| Metastases to Liver | — | UNRESOLVED | — |
| Neoplasms | Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Standard of Care for Metastatic Liver Cancer | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Overall Survival
- timeFrame
- Up to 10 years
- description
- The time interval from the date of initial diagnosis (or date of enrollment/surgery) to the date of death from any cause.
Secondary outcomes (2)
- measure
- Progression-Free Survival
- timeFrame
- Up to 10 years
- description
- Description: The time interval from the date of enrollment (or initial treatment) to the date of the first documented disease progression (local recurrence or distant metastasis) or death from any cause, whichever occurs first.
- measure
- Treatment-Related Adverse Events
- timeFrame
- Within 90 days post-treatment
- description
- The incidence and severity of postoperative complications or treatment-related adverse events, graded according to the Clavien-Dindo classification (for surgical complications) or CTCAE (Common Terminology Criteria for Adverse Events) version 5.0.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients with histologically or radiologically confirmed metastatic liver cancer. 2. Age ≥ 18 years. 3. Patients who have voluntarily signed the informed consent form. 4. Patients with complete baseline clinical data. Exclusion Criteria: 1. Patients with primary liver cancer (e.g., hepatocellular carcinoma). 2. Patients with other malignant tumors that may interfere with the evaluation of liver metastasis. 3. Patients who have previously participated in other interventional clinical trials. 4. Patients with severe cognitive disorders or communication barriers that prevent informed consent. 5. Patients with incomplete or missing key clinical data.
References
Publications (0)
Data not yet available